{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:23:37Z","timestamp":1779114217593,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,16]]},"DOI":"10.7759\/cureus.35069","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T17:58:25Z","timestamp":1676570305000},"source":"Crossref","is-referenced-by-count":3,"title":["Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma"],"prefix":"10.7759","author":[{"given":"Jaskaran","family":"Batra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvitha","family":"Ankireddypalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok K","family":"Kanugula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Gorle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim H","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017, 317:1338-48. 10.1001\/jama.2017.2719","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin JA","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016, 375:1054-67. 10.1056\/NEJMra1501993","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00082","article-title":"New therapies for advanced thyroid cancer","volume":"11","author":"Laha D","year":"2020","unstructured":"Laha D, Nilubol N, Boufraqech M. New therapies for advanced thyroid cancer. Front Endocrinol (Lausanne). 2020, 11:82. 10.3389\/fendo.2020.00082","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook GS","year":"2015","unstructured":"Falchook GS, Millward M, Hong D, et al.. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015, 25:71-7. 10.1089\/thy.2014.0123","journal-title":"Thyroid"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318148563d","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew E","year":"2007","unstructured":"Kebebew E, Weng J, Bauer J, et al.. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007, 246:466-70; discussion 470-1. 10.1097\/SLA.0b013e318148563d","journal-title":"Ann Surg"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.84.14_supplement.P4.232","article-title":"Guillain-Barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma. (P4.232)","volume":"84","author":"Maurice C","year":"2015","unstructured":"Maurice C, Marcus B & Mason W. Guillain-Barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma. (P4.232). Neurology. 2015, 84:232.","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000390","article-title":"Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma","volume":"27","author":"Taha T","year":"2017","unstructured":"Taha T, Tzuk-Shina T, Forschner I, Bar-Sela G. Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma. Melanoma Res. 2017, 27:632-4. 10.1097\/CMR.0000000000000390","journal-title":"Melanoma Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.720723","article-title":"Novel therapeutics in radioactive iodine-resistant thyroid cancer","volume":"12","author":"Fullmer T","year":"2021","unstructured":"Fullmer T, Cabanillas ME, Zafereo M. Novel therapeutics in radioactive iodine-resistant thyroid cancer. Front Endocrinol (Lausanne). 2021, 12:720723. 10.3389\/fendo.2021.720723","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061650","article-title":"Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation","volume":"12","author":"Meirson T","year":"2020","unstructured":"Meirson T, Asher N, Bomze D, Markel G. Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation. Cancers (Basel). 2020, 12:10.3390\/cancers12061650","journal-title":"Cancers (Basel)"},{"key":"ref10","unstructured":"NCI. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (2017). https.\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke C","year":"2014","unstructured":"Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria. Brain. 2014, 137:33-43. 10.1093\/brain\/awt285","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard SE","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FA, et al.. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019, 15:671-83. 10.1038\/s41582-019-0250-9","journal-title":"Nat Rev Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang W","year":"2002","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12:9-18. 10.1038\/sj.cr.7290105","journal-title":"Cell Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029506","article-title":"Identification of gene networks and pathways associated with Guillain-Barr\u00e9 syndrome","volume":"7","author":"Chang KH","year":"2012","unstructured":"Chang KH, Chuang TJ, Lyu RK, et al.. Identification of gene networks and pathways associated with Guillain-Barr\u00e9 syndrome. PLoS One. 2012, 7:e29506. 10.1371\/journal.pone.0029506","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.570586","article-title":"Functions of p38 MAP kinases in the central nervous system","volume":"13","author":"Asih PR","year":"2020","unstructured":"Asih PR, Prikas E, Stefanoska K, Tan AR, Ahel HI, Ittner A. Functions of p38 MAP kinases in the central nervous system. Front Mol Neurosci. 2020, 13:570586. 10.3389\/fnmol.2020.570586","journal-title":"Front Mol Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.10","article-title":"Thyroid carcinoma: molecular pathways and therapeutic targets","volume":"21","author":"Nikiforov YE","year":"2008","unstructured":"Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008, 21:S37-43. 10.1038\/modpathol.2008.10","journal-title":"Mod Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah V","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018, 36:7-13. 10.1200\/JCO.2017.73.6785","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022, 33:406-15. 10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg SM","year":"2015","unstructured":"Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015, 21:1028-35. 10.1158\/1078-0432.CCR-14-2915","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.6022","article-title":"Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma","volume":"35","author":"Shah MH","year":"2017","unstructured":"Shah MH, Wei L, Wirth LJ, et al.. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017, 35:6022. 10.1200\/JCO.2017.35.15_suppl.6022","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/137500-guillain-barre-syndrome-secondary-to-the-use-of-dabrafenib-and-trametinib-for-the-treatment-of-advanced-thyroid-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:36Z","timestamp":1707508356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/137500-guillain-barre-syndrome-secondary-to-the-use-of-dabrafenib-and-trametinib-for-the-treatment-of-advanced-thyroid-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.35069","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}